Stock Events

XOMA Royalty 

$26.28
50
-$0.2-0.76% Wednesday 20:00

Statistics

Day High
26.28
Day Low
26.25
52W High
26.51
52W Low
21.86
Volume
360
Avg. Volume
1,759
Mkt Cap
330.65M
P/E Ratio
-11.77
Dividend Yield
8.2%
Dividend
2.16

Upcoming

5
NOV
Earnings
 
2
JAN 25
Dividend Ex
Estimated
 
16
JAN 25
Dividend Payment
Estimated
 
2
APR 25
Dividend Ex
Estimated
 
15
APR 25
Dividend Payment
Estimated
 
3
JUL 25
Dividend Ex
Estimated
 
15
JUL 25
Dividend Payment
Estimated
 
3
OCT 25
Dividend Ex
Estimated
 
15
OCT 25
Dividend Payment
Estimated
 
2
JAN 26
Dividend Ex
Estimated
 

Dividends

8.2%Dividend Yield
Oct 24
$0.54
Jul 24
$0.54
Apr 24
$0.54
Jan 24
$0.54
Oct 23
$0.54
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
6.27%
1Y Growth
N/A

Earnings

5NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.87
-0.97
-0.06
0.84
Expected EPS
-0.436667
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XOMAP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals competes in the biotechnology industry focusing on developing and commercializing medicines for serious medical conditions, similar to XOMA's focus on antibody-based therapeutics.
AMGEN
AMGN
Mkt Cap179.38B
Amgen is a biopharmaceutical company that discovers, develops, manufactures, and delivers innovative human therapeutics, competing directly with XOMA in the biotech sector.
Biogen
BIIB
Mkt Cap29.83B
Biogen competes with XOMA in the biotechnology field, focusing on developing therapies for neurological and neurodegenerative diseases.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to XOMA, making them direct competitors.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals is involved in creating new possibilities in medicine to cure diseases and improve people's lives, competing with XOMA in the biotech innovation space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with XOMA in the development of novel therapeutics.
Incyte
INCY
Mkt Cap12.65B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, making it a competitor in the biopharmaceutical space alongside XOMA.
Nektar Therapeutics
NKTR
Mkt Cap235.62M
Nektar Therapeutics is involved in developing new treatment options in various therapeutic areas, competing with XOMA in the innovation of biologic drugs.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical focuses on developing and commercializing innovative biopharmaceuticals for rare diseases, competing with XOMA in targeting niche markets with specialized treatments.

About

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Show more...
CEO
Employees
13
Country
US
ISIN
US98419J3059

Listings

F
DE
X0M1.F
F
DE
X0M.F
LSE
GB
0M26.LSE
XNAS
US
XOMA